心房颤动卒中预防:未来展望
房颤相关缺血性卒中高发且复发风险高,抗栓治疗长期出血风险仍显著。本文回顾近30年房颤卒中预防进展,聚焦非维生素K拮抗剂口服抗凝药(NOAC)在风湿性心脏病、不明来源栓塞性卒中、认知 decline 等新适应症的研究,以及左心耳封堵、延长心电监测、秋水仙碱和因子XIa抑制等新策略。
要点
- NOAC在非瓣膜性房颤中较华法林更安全且等效。
- NOAC正探索用于风湿性心脏病、栓塞性卒中和认知下降。
- 左心耳封堵、延长监测、秋水仙碱和因子XIa抑制是新兴方向。
核心结论
- NOAC在非瓣膜性房颤卒中预防中较华法林更安全且等效。
- 多项新诊断与治疗策略正在临床试验中评估,以进一步降低卒中复发和出血风险。
研究设计与样本
- 综述总结过去30年房颤卒中预防的主要进展,并聚焦正在进行的临床试验中的新诊断和治疗方法。
主要发现
- NOAC被证明在非瓣膜性房颤卒中预防中较华法林更安全且同等有效。
- NOAC正在风湿性心脏病、近期不明来源栓塞性卒中伴心源性栓塞间接证据、以及房颤相关血管介导认知下降中接受研究。
- 多项试验评估近期缺血性卒中后NOAC启动的最佳时机,以及既往颅内出血房颤患者使用NOAC的获益风险比。
- 正在进行的试验探讨左心耳封堵在房颤一级和二级卒中预防中的作用,包括高出血风险患者。
- 通过智能手机应用或植入式心脏设备延长心脏监测以检测亚临床房颤的附加价值,以及隐匿性阵发性房颤的最佳医疗管理,是研究热点。
临床怎么用
- 非瓣膜性房颤卒中预防可优先考虑NOAC而非华法林。
- 对近期缺血性卒中或既往颅内出血的房颤患者,NOAC启动时机和获益风险比需个体化评估。
- 高出血风险房颤患者可关注左心耳封堵的临床试验证据。
- 延长心脏监测有助于发现亚临床房颤,但最佳管理策略尚待明确。
局限性
- 本文为综述,未报告原始研究的具体样本量、阈值或统计值。
- 所述新策略大多处于临床研究阶段,尚未形成常规实践推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ischemic strokes related to atrial fibrillation are highly prevalent, presenting with severe neurologic syndromes and associated with high risk of recurrence. Although advances have been made in both primary and secondary stroke prevention for patients with atrial fibrillation, the long-term risks for stroke recurrence and bleeding complications from antithrombotic treatment remain substantial. We summarize the major advances in stroke prevention for patients with atrial fibrillation during the past 30 years and focus on novel diagnostic and treatment approaches currently under investigation in ongoing clinical trials. Non-vitamin K antagonist oral anticoagulants have been proven to be safer and equally effective compared with warfarin in stroke prevention for patients with nonvalvular atrial fibrillation. Non-vitamin K antagonist oral anticoagulants are being investigated for the treatment of patients with atrial fibrillation and rheumatic heart disease, for the treatment of patients with recent embolic stroke of undetermined source and indirect evidence of cardiac embolism, and in the prevention of vascular-mediated cognitive decline in patients with atrial fibrillation. Multiple clinical trials are assessing the optimal timing of non-vitamin K antagonist oral anticoagulant initiation after a recent ischemic stroke and the benefit:harm ratio of non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation and history of previous intracranial bleeding. Ongoing trials are addressing the usefulness of left atrial appendage occlusion in both primary and secondary stroke prevention for patients with atrial fibrillation, including those with high risk of bleeding. The additive value of prolonged cardiac monitoring for subclinical atrial fibrillation detection through smartphone applications or implantable cardiac devices, together with the optimal medical management of individuals with covert paroxysmal atrial fibrillation, is a topic of intensive research interest. Colchicine treatment and factor XIa inhibition constitute 2 novel pharmacologic approaches that might provide future treatment options in the secondary prevention of cardioembolic stroke attributable to atrial fibrillation.
引用
- Katsanos AH, Kamel H, Healey JS, et al. Stroke Prevention in Atrial Fibrillation: Looking Forward. Circulation. 2020. PMID: 33315494. doi:10.1161/CIRCULATIONAHA.120.049768
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。